Nutra Pharma Provides Update on US Military and US Government Registrations
August 19 2013 - 8:30AM
Business Wire
Nutra Pharma Corp. (OTCQB: NPHC), a biotechnology company that
is developing treatments for Adrenomyeloneuropathy (AMN), HIV and
Multiple Sclerosis (MS), has provided an update on their efforts to
register their Nyloxin™ line of pain relievers with US Governmental
agencies. In December 2012, the Company announced that it was
introducing a stronger version of its over-the-counter (OTC) pain
reliever, Nyloxin™, to be called Nyloxin™ Military
Strength. Nutra Pharma is registering the Nyloxin™ Military
Strength as well as Nyloxin™ and Nyloxin™ Extra Strength with US
government agencies that will allow for the eventual sales and
distribution of these products into the active military, US
military base stores and foreign embassies.
"Nutra Pharma has successfully registered with the centralized
"SAM" contractor portal, obtained the DUN & Bradstreet rating
and the CAGE (Commercial & Government Entity) code to conduct
business with the Federal Government," commented Rick Horn, current
consultant and retired military Contracting Officer. "Nutra Pharma
is now registered with the Defense Commissary Agency and the Base
Exchange Services at all active military bases to market their
products. In addition, Nutra Pharma has applied for a DAPA
(Distribution & Pricing Agreement) with Defense Logistics
Agency Philadelphia to market the products directly with any
federal agency under this contract vehicle," he continued. "We have
also submitted the Nyloxin products to the Army's Fort Dietrich New
Products & Ideas Center for evaluation. They have stated that
these products fall within the parameters of the program," Mr. Horn
concluded.
Over the past few years, the U.S. Department of Defense has been
reporting an increase in the use and abuse of prescription
medications, particularly opiates. In 2009, close to 3.8 million
prescriptions for pain relievers were written in the military. This
staggering number was more than a 400% increase from the number of
prescriptions written in the military in 2001. But prescription
drugs are not the only issue. The most common and seemingly
harmless way to treat pain is with non steroidal, anti-inflammatory
drugs (NSAIDS). But there are risks. Overuse can cause nausea,
vomiting, diarrhea, heartburn, ulcers and internal bleeding. In
severe cases chest pain, heart failure, kidney dysfunction and
life-threatening allergic reactions can occur. It is reported that
approximately 7,600 people in America die from NSAID use and some
78,000 are hospitalized.
“Our hope is that with Nyloxin, we can greatly reduce the
instances of opiate abuse and overuse of NSAIDS in high risk groups
like the US military,” said Rik J Deitsch, Chairman and CEO of
Nutra Pharma Corporation. “Our goal for Nyloxin over the next
several years is to be the number one choice that people turn to
for chronic pain relief,” he concluded.
Ibuprofen, also an NSAID, has been of particular concern in the
military. The terms “Ranger Candy” and “Military Candy” refer to
the service men and women who are said to use 800mg doses of
Ibuprofen to control their pain. But when taking anti-inflammatory
Ibuprofen in high doses for chronic pain, there is potential for
critical health risks; abuse can lead to serious stomach problems,
internal bleeding and even kidney failure. There are significantly
greater health risks when abuse of this drug is combined with
alcohol intake.
Nyloxin™ is an over-the-counter (OTC) pain reliever clinically
proven to treat moderate to severe (Stage 2) chronic pain. Nyloxin™
is currently available in the United States as an oral spray for
treating back pain, neck aches, headaches, joint pain, migraines,
and neuralgia, and as a topical gel for treating joint pain, neck
pain, arthritis pain, and pain from repetitive stress. In addition
to its everyday strength formulation, Nyloxin™ is also offered in
an extra strength formula for more advanced, Stage 3, chronic pain.
The new Nyloxin™ Military Strength represents the strongest version
of Nyloxin™ available.
About Nutra Pharma Corp.
Nutra Pharma Corporation operates as a biotechnology company
specializing in the acquisition, licensing, and commercialization
of pharmaceutical products and technologies for the management of
neurological disorders, cancer, autoimmune, and infectious
diseases, including Multiple Sclerosis (MS), Human Immunodeficiency
Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain. The Company
markets several drug products for sale for the treatment of pain
under the brands Cobroxin® and Nyloxin™. For additional information
about Nutra Pharma, visit: http://www.NutraPharma.com or
http://www.nyloxin.net.
SEC Disclaimer
This press release contains forward-looking statements. The
words or phrases "would be," "will allow," "intends to," "will
likely result," "are expected to," "will continue," "is
anticipated," "estimate," "project," or similar expressions are
intended to identify "forward-looking statements." Actual results
could differ materially from those projected in Nutra Pharma's
("the Company") business plan. The update on US governmental
registrations should not be construed as an indication in any way
whatsoever of the future value of the Company’s common stock or its
present or future financial condition. The Company's filings may be
accessed at the SEC's Edgar system at www.sec.gov. Statements made
herein are as of the date of this press release and should not be
relied upon as of any subsequent date. The Company cautions readers
not to place reliance on such statements. Unless otherwise required
by applicable law, we do not undertake, and we specifically
disclaim any obligation, to update any forward-looking statements
to reflect occurrences, developments, unanticipated events or
circumstances after the date of such statement.
Contact:
Nutra Pharma Corp.
Nina Goldstein
877-895-5647
IR@nutrapharma.com
Nutra Pharma (CE) (USOTC:NPHC)
Historical Stock Chart
From Aug 2024 to Sep 2024
Nutra Pharma (CE) (USOTC:NPHC)
Historical Stock Chart
From Sep 2023 to Sep 2024